The estimated Net Worth of Max Reinhardt is at least $7.21 Milion dollars as of 6 June 2023. Mr. Reinhardt owns over 2,153 units of Pacira BioSciences Inc stock worth over $379,925 and over the last 5 years he sold PCRX stock worth over $2,251,107. In addition, he makes $4,575,040 as President at Pacira BioSciences Inc.
Sign up
Mr. Reinhardt PCRX stock SEC Form 4 insiders trading
Max has made over 10 trades of the Pacira BioSciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,153 units of PCRX stock worth $82,718 on 6 June 2023.
The largest trade he's ever made was exercising 37,500 units of Pacira BioSciences Inc stock on 18 April 2022 worth over $1,595,250. On average, Max trades about 8,088 units every 71 days since 2019. As of 6 June 2023 he still owns at least 29,225 units of Pacira BioSciences Inc stock.
You can see the complete history of Mr. Reinhardt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Max Reinhardt biography
Max Reinhardt serves as President of the Company. Prior to joining Pacira, he served as Vice President of Marketing for DePuy Synthes Sales, Inc. ("DePuy Synthes"), part of the Johnson & Johnson Medical Devices Companies ("Johnson & Johnson"), from March 2016 until May 2019. Prior to serving as Vice President of Marketing at DePuy Synthes, Mr. Reinhardt was Director of Sales and Marketing for DePuy Spine and Vice President of US Sales for DePuy Spine. In 2011, he was named Vice President, Worldwide Marketing of DePuy Synthes, a position in which he played a key role in the acquisition and integration of Synthes Spine. In 2012, he was named Worldwide President, DePuy Synthes Spine, and led the spine business through the first two years of integration. Prior to Johnson & Johnson, Mr. Reinhardt served in sales leadership roles at both Olympus KeyMed and STERIS Corporation in the United Kingdom.
What is the salary of Max Reinhardt?
As the President of Pacira BioSciences Inc, the total compensation of Max Reinhardt at Pacira BioSciences Inc is $4,575,040. There are 1 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.
How old is Max Reinhardt?
Max Reinhardt is 49, he's been the President of Pacira BioSciences Inc since 2019. There are 20 older and 5 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
What's Max Reinhardt's mailing address?
Max's mailing address filed with the SEC is 3451 PLANO PARKWAY, , LEWISVILLE, TX, 75056.
Insiders trading at Pacira BioSciences Inc
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon a Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
What does Pacira BioSciences Inc do?
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
What does Pacira BioSciences Inc's logo look like?
Complete history of Mr. Reinhardt stock trades at Orthofix Medical Inc a Pacira BioSciences Inc
Pacira BioSciences Inc executives and stock owners
Pacira BioSciences Inc executives and other stock owners filed with the SEC include:
-
David Stack,
Chairman of the Board, Chief Executive Officer -
Max Reinhardt,
President -
Dennis McLoughlin,
Chief Commercial Officer -
Kristen Williams,
Chief Administrative Officer, Secretary -
Roy Winston,
Chief Clinical Officer -
David M. Stack,
Chairman & CEO -
Charles Reinhart,
Chief Financial Officer -
Dr. Roy Winston M.D.,
Chief Medical Officer -
Christopher Christie,
Director -
Max Reinhardt,
Pres of Rest of World -
Dr. Jonathan Slonin M.D.,
Chief Clinical Officer -
Kristen Williams,
Chief Admin. Officer & Sec. -
Charles A. Reinhart III, CPA, M.B.A.,
Chief Financial Officer -
Paul Hastings,
Lead Independent Director -
Laura Brege,
Independent Director -
John Longenecker,
Independent Director -
Mark Kronenfeld,
Independent Director -
Yvonne Greenstreet,
Independent Director -
Mark Froimson,
Independent Director -
Gary Pace,
Independent Director -
Susan Mesco,
IR Contact Officer -
Andreas Wicki,
Independent Director -
Charles Laranjeira,
Chief Technical Officer -
Kristen Williams J.D.,
Chief Admin. Officer & Sec. -
Daryl Gaugler,
Chief Operating Officer -
Robert J. Weiland,
Sr. VP of Alliance Management -
Richard Kahr,
VP of HR -
Charles Laranjeira,
Chief Technical Officer -
Lauren Bullaro Riker,
Principal Accounting Officer & VP of Fin. -
Dennis L Winger,
Director -
Scott Braunstein,
SVP, Strategy & Corp. Dev. -
Robert J. Weiland,
Chief Commercial Officer -
Richard Scranton,
Chief Scientific Officer -
James B Jones,
SVP & Chief Medical Officer -
James S Scibetta,
Chief Financial Officer -
Gary Patou,
Director -
Taunia Markvicka,
Vice President, Commercial -
Advisors Llc Orbi Med Capit...,
-
Venture Partners Vi Lp Sand...,
-
Bio Ventures Iv Qp Lpmpm Bi...,
-
Bio Ventures Iv Qp Lp Scopa...,
-
Carl L Gordon,
Director -
Bio Ventures Iv Qp Lpmpm Bi...,
-
Venture Partners Vi Lp Sand...,
-
Luke Evnin,
Director -
John Pratt,
General Manager, San Diego -
Vaughn Mgadicke Ansbert Kai...,
-
Bioventures Cayman Ltd Hbm,
10% owner -
Fred A Middleton,
Director -
Venture Partners Vi Lp Sand...,
-
Venture Partners Vi Lp Sand...,
-
Abraham Ceesay,
Director -
Alethia Young,
Director -
Marcelo Bigal,
Director -
Michael J. Yang,
Director -
Donald C. Manning,
Chief Medical Officer -
Lauren Riker,
Senior Vice President, Finance -
Anthony Molloy,
Chief Lgl & Compliance Officer -
Daryl Gaugler,
Chief Operating Officer -
Ronald J. Jr. Ellis,
Chief Strategy Officer -
Jonathan Slonin,
Chief Medical Officer -
Frank D. Lee,
Chief Executive Officer